HUTCHMED提交6-K文件，披露ORPATHYS与TAGRISSO欧洲及日本监管申报获受理审评
6-K - HUTCHMED (China) Ltd (0001648257) (Filer)
HUTCHMED提交的6-K文件附有新闻稿，称ORPATHYS联合TAGRISSO用于MET驱动的EGFR突变肺癌的监管申报已获欧洲和日本受理审评。文件日期为11月2日，属于外国私人发行人报告；材料未提供审评结果。
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
For the Month of November 2026
Commission File Number: 001-37710
HUTCHMED (CHINA) LIMITED
(Translation of registrant’s name into English)
48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ⌧ Form 40-F ◻
HUTCHMED (CHINA) LIMITED
Form 6-K
EXHIBIT INDEX
Exhibit No. | | Description |
| | |
Exhibit 99.1 | | Press release relating to HUTCHMED announces regulatory filings accepted for review for ORPATHYS® plus TAGRISSO® in MET-driven EGFR-mutated lung cancer in Europe and Japan |
| | |
| | |
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| HUTCHMED (CHINA) LIMITED | |
| | |
| | |
| By: | /s/ Johnny Cheng |
| Name: | Johnny Cheng |
| Title: | Chief Financial Officer |
Date: November 2, 2026
3
来源：SEC EDGAR · 本站存档